The Biostatistics and Computational Biology Core of the Cancer Center was established in 1994 with the goal of assuring biostatistical and computational biology support to cancer-related research at UCSF. In 2011, at the suggestion of an external advisory board, the Biostatistics and Computational Biology Core was split into two separate cores: 1) Biostatistics Core and 2) Computational Biology Core. This division was undertaken as a reflection of the distinct needs of projects focusing on clinical and laboratory studies involving standard statistical approaches and those involving genomics and requiring high performance computing services. Because some projects may require both types of support, the Cores are closely coordinated. There is no overlap of services provided by each core, and funding is not duplicated for the same services in two cores. The Computational Biology Core provides partial support to six computational biologists, biostatisticians, and programmers, half of whom are UCSF faculty, who together cover the extensive breadth of expertise required for Cancer Center projects. The Core has the expertise to support genomics, proteomics, and all other types of """"""""omics"""""""", as well as network and pathway analysis. The core works with many types of data including microarray data, second generation sequencing data, and other types of high-throughput data. The Core provides services on a charge back basis, as collaborators on grants, or without charge when developing research projects for grant funding. One major goal of the Core is to assure that novel analytical approaches developed in one project are rapidly available to all Cancer Center investigators. The five major functions of the Computational Biology Core within the Cancer Center are: (1) scientific consultation for problems relating to computational biology;(2) data analysis for such projects;(3) grant development, including design of experiments, initial data analyses and writing;(4) education, in both formal and informal settings;and (5) software development and training. Core personnel also perform computational biology research within the context of Cancer Center projects, or on projects for which they have obtained independent funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693948
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$400,448
Indirect Cost
$146,874
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131:
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279
Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380
Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794

Showing the most recent 10 out of 192 publications